Investigators from the Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, led by Ying Zhu, MD, PhD, who studied the ocular effects of repeated intravitreal ...

The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting. Innovent Biologics recently announced its ...

Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation. Joining the Eye Care Network in ...

Preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) was recently announced by ANI Pharmaceuticals. 1 Cotrophin Gel is a prescription injection indicated for ...

The Retinal Genix plans to use the facility to further the development of its DNA/RNA/GPS Pharmaco-Genetic Mapping platform. RetinalGenix has signed a new laboratory lease agreement with life science ...

In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab. At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, ...

Chengdu Origen Biotechnology Co, Ltd. And Vanotech Ltd. recently announced the dosing of the first patient in the VAN-2401 multi-center phase 1 clinical trial (NCT06825858). 1 The VAN-2401 clinical ...

The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD. At the 2025 Association for Research in Vision ...

KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation. KIO-104, a small molecular DHODH inhibitor, works by suppressing T cell replication and function. The ...

Lukas Scheibler, PhD, has been appointed as chief research and development officer and Graham Cooper as chief financial officer of Tavo Biotherapeutics, the company recently announced. 1 “I am ...